Nintedanib Accord: Europe’s First Generic Nintedanib—What to Know About Origins, Patents, Benefits, Risks, and Trial Safety

Short take: Nintedanib Accord is the EU-authorised generic of Boehringer Ingelheim’s nintedanib (brand: Ofev). It slows lung-function decline across several fibrosing interstitial lung diseases (ILDs). Its biggest upsides are consistent efficacy across IPF, progressive-phenotype ILDs, and SSc-ILD, plus an oral regimen and now a lower-cost generic option. The trade-offs are predictable: frequent GI side-effects (especially diarrhoea), liver-enzyme elevations that require monitoring, and class-typical warnings (bleeding, GI perforation/ischemic colitis, hypertension, wound-healing). European Medicines Agency (EMA)+1

What is Nintedanib Accord?

What it treats (EU):

Idiopathic pulmonary fibrosis (IPF)
Other chronic fibrosing ILDs with a progressive phenotype
Systemic-sclerosis-associated ILD (SSc-ILD)
(There is also paediatric use for clinically significant progressive fibrosing ILDs from age 6.) European Medicines Agency (EMA)+1

Status & holder: Generic medicine authorised EU-wide on 19 April 2024. Marketing authorisation holder: Accord Healthcare S.L.U. European Medicines Agency (EMA)

How it works: An oral, small-molecule tyrosine kinase inhibitor targeting PDGFR, FGFR and VEGFR families (and others), blocking pathways implicated in fibrosis. European Medicines Agency (EMA)

Who Developed and Patented the Originator?

Developer / reference product: Boehringer Ingelheim developed nintedanib; the EU reference medicine is Ofev. European Medicines Agency (EMA)Boehringer Ingelheim
Patent & SPC (EU context): Public UPC/European IP reporting indicates Boehringer’s core patent protection runs to 21 December 2025, with a Supplementary Protection Certificate (SPC) to 9 April 2026 in (at least) some EU/UPC jurisdictions. These dates frame when generics can actually launch per country. Pinsent Masons Mewburn Juve Patent

Note: U.S. patent timelines differ (some sources project later generic entry); EU timelines above are what matter for Nintedanib Accord. DrugPatentWatch

How Well Does It Work? (Pros)

Slows FVC decline in IPF: Two replicate Phase 3 INPULSIS trials showed a statistically significant reduction in the annual rate of decline in FVC vs placebo. European Medicines Agency (EMA)
Works across progressive fibrosing ILDs: INBUILD demonstrated slowed FVC decline across a basket of progressive ILDs—supporting the “progressive phenotype” indication. European Medicines Agency (EMA)
Benefit in SSc-ILD: SENSCIS showed a slower decline in lung function vs placebo. European Medicines Agency (EMA)
Oral, twice-daily regimen with established dose-interruption/-reduction rules to manage tolerability. European Medicines Agency (EMA)
Paediatric extension (EU): Can be used from age 6 for clinically significant progressive fibrosing ILDs under specialist teams, with growth and dental monitoring. European Medicines Agency (EMA)

Trade-offs (Cons)

GI tolerability is the price of admission: Diarrhoea is very common and often starts within the first 3 months; anti-diarrhoeals and dose adjustments are frequently needed. In 52-week trials, diarrhoea occurred in ~62–76% on nintedanib vs ~18–32% on placebo, with 2–4% severe and ~4–7% discontinuations due to diarrhoea (trial-dependent). European Medicines Agency (EMA)
Liver-enzyme elevations / drug-induced liver injury: Requires baseline and periodic monitoring; elevations were clearly more frequent than with placebo in IPF trials. European Medicines Agency (EMA)
Class-typical vascular/bleeding considerations: Because of VEGF-pathway effects, warnings include bleeding risk, hypertension, thromboembolic events, and peri-surgical wound-healing concerns. European Medicines Agency (EMA)
Allergy & pregnancy: Contraindicated in pregnancy and in those with peanut/soya hypersensitivity (excipients). European Medicines Agency (EMA)

Safety Issues Observed in Trials (and After)

Very common / common in trials

Diarrhoea, nausea, vomiting, abdominal pain; weight loss is not unusual over time. Management often involves loperamide, dose interruption or reduction. European Medicines Agency (EMA)
Liver-related labs: ALT/AST increases and rare liver injury; monitor and adjust/interrupt if needed. European Medicines Agency (EMA)

Important warnings/precautions (trials + post-marketing signal)

Bleeding risk (especially GI); use caution with anticoagulants/antiplatelets; interrupt for major bleeding. European Medicines Agency (EMA)
GI perforation & ischaemic colitis: Rare but serious events—including some fatal—reported post-marketing; avoid in high-risk settings (e.g., recent abdominal surgery, diverticular disease, peptic ulcer; caution with NSAIDs/steroids). Permanently discontinue if they occur. European Medicines Agency (EMA)
Hypertension: Monitor and treat as appropriate. European Medicines Agency (EMA)
Nephrotic-range proteinuria / thrombotic microangiopathy (TMA): Very rare signals; stop if TMA is suspected. European Medicines Agency (EMA)
Posterior reversible encephalopathy syndrome (PRES): Rare cases reported; discontinue if suspected. European Medicines Agency (EMA)
Wound-healing impairment: Interrupt around major surgery; initiate only after adequate healing. European Medicines Agency (EMA)
QT: No signal seen in the programme, but caution in those at risk for QT prolongation. European Medicines Agency (EMA)

Paediatrics (EU-label): Limited data; the most frequent AEs mirrored adults (diarrhoea, vomiting, nausea, abdominal pain, headache). Ongoing concerns include potential effects on growth plates and tooth development—hence scheduled monitoring. Long-term safety in children remains uncertain. European Medicines Agency (EMA)

Practical Considerations

Dosing: Oral capsules with food; do not open or crush (there are instructions for mixing briefly with a small amount of soft food to swallow whole). Dose reductions and treatment interruptions are built into the label to manage adverse events. European Medicines Agency (EMA)
Drug interactions: Substrate of P-glycoprotein; strong P-gp inhibitors (e.g., ketoconazole) increase exposure; strong inducers (e.g., rifampicin) reduce it. European Medicines Agency (EMA)
Concomitant pirfenidone: No relevant PK interaction detected, but overlapping GI/hepatic toxicity means additive side-effects are plausible; benefit-risk of dual antifibrotics isn’t established in the EU label. European Medicines Agency (EMA)

Why the “Accord” version matters

The 2024 EU authorisation of Nintedanib Accord introduces a generic alternative to Ofev, likely improving access as patent/SPC barriers expire country-by-country in late 2025–2026. Roll-out timing can vary with national IP and reimbursement decisions. European Medicines Agency (EMA)Pinsent Masons Mewburn

Bottom line

If you’re treating IPF, progressive-phenotype ILDs, or SSc-ILD, nintedanib has consistent, label-anchored efficacy in slowing lung-function decline—and now exists as an EU-approved generic (Nintedanib Accord). Expect GI side-effects and liver-test monitoring; screen for risk factors tied to bleeding, GI perforation/ischemic colitis, hypertension, and peri-operative healing. For children (≥6 years), use within experienced multidisciplinary teams and follow the label’s growth/dental monitoring guidance. European Medicines Agency (EMA)+1

Sources

EMA EPAR page for Nintedanib Accord (overview, authorisation date, MAH, indications). European Medicines Agency (EMA)
EU Summary of Product Characteristics / Package Leaflet for Nintedanib Accord (mechanism, efficacy summaries from INPULSIS/INBUILD/SENSCIS, adverse reactions, warnings). European Medicines Agency (EMA)
Boehringer Ingelheim product pages for Ofev (developer/originator context). Boehringer Ingelheim
European patent/SPC context for nintedanib (UPC/European IP reporting on expiry dates). Pinsent Masons Mewburn Juve Patent

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.